Intraarterial therapies for primary liver cancer: state of the art

References

• Otto G, Schuchmann M, Hoppe-Lotichius M et al. How to decide about liver transplantation in patients with hepatocellular carcinoma: size and number of lesions or response to TACE? J. Hepatol. 59(2), 279–284 (2013).
   PubMed Web of Science ®Google Scholar
• Schumacher PA, Powell JJ, MacNeill AJ et al. Multimodal therapy for hepatocellular carcinoma: a complementary approach to liver transplantation. Ann. Hepatol. 9(1), 23–32 (2010).
   PubMed Web of Science ®Google Scholar
• Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 148(2), 397–401 (1983).
   PubMed Web of Science ®Google Scholar
• Tadavarthy SM, Knight L, Ovitt TW, Snyder C, Amplatz K. Therapeutic transcatheter arterial embolization. Radiology 112(1), 13–16 (1974).
   PubMed Web of Science ®Google Scholar
• Lammer J, Malagari K, Vogl T et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc. Intervent. Radiol. 33(1), 41–52 (2010).
   PubMed Web of Science ®Google Scholar
• Sergio A, Cristofori C, Cardin R et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am. J. Gastroenterol. 103(4), 914–921 (2008).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4), 378–390 (2008).
   PubMed Web of Science ®Google Scholar
• Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J. Clin. Oncol. 29(30), 3960–3967 (2011).
   PubMed Web of Science ®Google Scholar
• Salem R, Gilbertsen M, Butt Z et al. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin. Gastroenterol. Hepatol. 11(10), 1358–1365 e1 (2013).
   PubMed Web of Science ®Google Scholar
• Pleguezuelo M, Marelli L, Misseri M et al. TACE versus TAE as therapy for hepatocellular carcinoma. Expert Rev. Anticancer Ther. 8(10), 1623–1641 (2008).
   PubMed Web of Science ®Google Scholar
• Yumoto Y, Jinno K, Tokuyama K et al. Hepatocellular carcinoma detected by iodized oil. Radiology 154(1), 19–24 (1985).
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M; American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology 53(3), 1020–1022 (2011).
   PubMed Web of Science ®Google Scholar
• Sahara S, Kawai N, Sato M et al. Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer Drugs (epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma. Cardiovasc. Intervent. Radiol. 35(6), 1363–1371 (2012).
   PubMed Web of Science ®Google Scholar
• Brown DB, Gould JE, Gervais DA et al. Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J. Vasc. Interv. Radiol. 20(7 Suppl.), S425–S434 (2009).
   PubMed Web of Science ®Google Scholar
• Laurent A, Beaujeux R, Wassef M, Rufenacht D, Boschetti E, Merland JJ. Trisacryl gelatin microspheres for therapeutic embolization, I: development and in vitro evaluation. AJNR Am. J. Neuroradiol. 17(3), 533–540 (1996).
   PubMed Web of Science ®Google Scholar
• Hong K, Khwaja A, Liapi E, Torbenson MS, Georgiades CS, Geschwind JF. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin. Cancer Res. 12(8), 2563–2567 (2006).
   PubMed Web of Science ®Google Scholar
• Reyes DK, Vossen JA, Kamel IR et al. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J. 15(6), 526–532 (2009).
   PubMed Web of Science ®Google Scholar
• Constantin M, Fundueanu G, Bortolotti F, Cortesi R, Ascenzi P, Menegatti E. Preparation and characterisation of poly(vinyl alcohol)/cyclodextrin microspheres as matrix for inclusion and separation of drugs. Int. J. Pharm. 285(1–2), 87–96 (2004).
   PubMed Web of Science ®Google Scholar
• Qian J, Truebenbach J, Graepler F et al. Application of poly-lactide-co-glycolide-microspheres in the transarterial chemoembolization in an animal model of hepatocellular carcinoma. World J. Gastroenterol. 9(1), 94–98 (2003).
   PubMed Web of Science ®Google Scholar
• Gonzalez MV, Tang Y, Phillips GJ et al. Doxorubicin eluting beads-2: methods for evaluating drug elution and in-vitro: in-vivo correlation. J. Mater. Sci. Mater. Med. 19(2), 767–775 (2008).
   PubMed Web of Science ®Google Scholar
• Lewis AL, Gonzalez MV, Leppard SW et al. Doxorubicin eluting beads - 1: effects of drug loading on bead characteristics and drug distribution. J. Mater. Sci. Mater. Med. 18(9), 1691–1699 (2007).
   PubMed Web of Science ®Google Scholar
• Lewis AL, Gonzalez MV, Lloyd AW et al. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J. Vasc. Interv. Radiol. 17(2 Pt 1), 335–342 (2006).
   PubMed Web of Science ®Google Scholar
• Namur J, Citron SJ, Sellers MT et al. Embolization of hepatocellular carcinoma with drug-eluting beads: doxorubicin tissue concentration and distribution in patient liver explants. J. Hepatol. 55(6), 1332–1338 (2011).
   PubMed Web of Science ®Google Scholar
• Seki A, Hori S, Kobayashi K, Narumiya S. Transcatheter arterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres for 135 hepatocellular carcinoma patients: single-center experience. Cardiovasc. Intervent. Radiol. 34(3), 557–565 (2011).
   PubMed Web of Science ®Google Scholar
• Huppert P, Wenzel T, Wietholtz H. Transcatheter Arterial Chemoembolization (TACE) of Colorectal Cancer Liver Metastases by Irinotecan-Eluting Microspheres in a Salvage Patient Population. Cardiovasc. Intervent. Radiol. doi:10.1007/s00270-013-0632-0 (2013) (Epub ahead of print).
   Web of Science ®Google Scholar
• van Malenstein H, Maleux G, Vandecaveye V et al. A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma. Onkologie 34(7), 368–376 (2011).
   PubMedGoogle Scholar
• Deschamps F, Rao P, Teriitehau C et al. Percutaneous femoral implantation of an arterial port catheter for intraarterial chemotherapy: feasibility and predictive factors of long-term functionality. J. Vasc. Interv. Radiol. 21(11), 1681–1688 (2010).
   PubMed Web of Science ®Google Scholar
• De Luna W, Sze DY, Ahmed A et al. Transarterial chemoinfusion for hepatocellular carcinoma as downstaging therapy and a bridge toward liver transplantation. Am. J. Transplant. 9(5), 1158–1168 (2009).
   PubMed Web of Science ®Google Scholar
• Kemeny NE, Niedzwiecki D, Hollis DR et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J. Clin. Oncol. 24(9), 1395–1403 (2006).
   PubMed Web of Science ®Google Scholar
• Bruix J, Llovet JM, Castells A et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 27(6), 1578–1583 (1998).
   PubMed Web of Science ®Google Scholar
• Feng M, Normolle D, Pan CC et al. Dosimetric analysis of radiation-induced gastric bleeding. Int. J. Radiat. Oncol. Biol. Phys. 84(1), e1–e6 (2012).
   Web of Science ®Google Scholar
• Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten Haken RK. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int. J. Radiat. Oncol. Biol. Phys. 53(4), 810–821 (2002).
   PubMed Web of Science ®Google Scholar
• Hata M, Tokuuye K, Sugahara S et al. Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus. Cancer 104(4), 794–801 (2005).
   PubMed Web of Science ®Google Scholar
• Chakravarty R, Dash A, Pillai MR. Availability of yttrium-90 from strontium-90: a nuclear medicine perspective. Cancer Biother. Radiopharm. 27(10), 621–641 (2012).
   PubMed Web of Science ®Google Scholar
• Geschwind JF, Salem R, Carr BI et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 127(5 Suppl. 1), S194–S205 (2004).
   PubMed Web of Science ®Google Scholar
• Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations. J. Vasc. Interv. Radiol. 17(8), 1251–1278 (2006).
   PubMed Web of Science ®Google Scholar
• Gil-Alzugaray B, Chopitea A, Inarrairaegui M et al. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology 57(3), 1078–1087 (2013).
   PubMed Web of Science ®Google Scholar
• McCann JW, Larkin AM, Martino LJ, Eschelman DJ, Gonsalves CF, Brown DB. Radiation emission from patients treated with selective hepatic radioembolization using yttrium-90 microspheres: are contact restrictions necessary? J. Vasc. Interv. Radiol. 23(5), 661–667 (2012).
   PubMed Web of Science ®Google Scholar
• Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 379(9822), 1245–1255 (2012).
   PubMed Web of Science ®Google Scholar
• Sangro B, Inarrairaegui M, Bilbao JI. Radioembolization for hepatocellular carcinoma. J. Hepatol. 56(2), 464–473 (2012).
   PubMed Web of Science ®Google Scholar
• Brown DB, Nikolic B, Covey AM et al. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J. Vasc. Interv. Radiol. 23(3), 287–294 (2012).
   PubMed Web of Science ®Google Scholar
• Dhand S, Gupta R. Hepatic transcatheter arterial chemoembolization complicated by postembolization syndrome. Semin. Intervent. Radiol. 28(2), 207–211 (2011).
   PubMedGoogle Scholar
• Bouvier A, Ozenne V, Aube C et al. Transarterial chemoembolisation: effect of selectivity on tolerance, tumour response and survival. Eur. Radiol. 21(8), 1719–1726 (2011).
   PubMed Web of Science ®Google Scholar
• Varela M, Real MI, Burrel M et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J. Hepatol. 46(3), 474–481 (2007).
   PubMed Web of Science ®Google Scholar
• Riaz A, Lewandowski RJ, Kulik LM et al. Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J. Vasc. Interv. Radiol. 20(9), 1121–1130; quiz 1131 (2009).
   PubMed Web of Science ®Google Scholar
• Salem R, Lewandowski RJ, Atassi B et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J. Vasc. Interv. Radiol. 16(12), 1627–1639 (2005).
   PubMed Web of Science ®Google Scholar
• Giuliante F, Ardito F, Pinna AD et al. Liver resection for hepatocellular carcinoma ≤3 cm: results of an Italian multicenter study on 588 patients. J. Am. Coll. Surg. 215(2), 244–254 (2012).
   PubMed Web of Science ®Google Scholar
• Facciuto ME, Koneru B, Rocca JP et al. Surgical treatment of hepatocellular carcinoma beyond Milan criteria. Results of liver resection, salvage transplantation, and primary liver transplantation. Ann. Surg. Oncol. 15(5), 1383–1391 (2008).
   PubMed Web of Science ®Google Scholar
• Salem R, Lewandowski RJ, Mulcahy MF et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 138(1), 52–64 (2010).
   PubMed Web of Science ®Google Scholar
• Takaki S, Sakaguchi H, Anai H et al. Long-term outcome of transcatheter subsegmental and segmental arterial chemoemobolization using lipiodol for hepatocellular carcinoma. Cardiovasc. Intervent. Radiol. 35(3), 544–554 (2012).
   PubMed Web of Science ®Google Scholar
• Lewandowski RJ, Mulcahy MF, Kulik LM et al. Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. Radiology 255(3), 955–965 (2010).
   PubMed Web of Science ®Google Scholar
• Terzi E, Golfieri R, Piscaglia F et al. Response rate and clinical outcome of HCC after first and repeated cTACE performed “on demand”. J. Hepatol. 57(6), 1258–1267 (2012).
   PubMed Web of Science ®Google Scholar
• Malagari K, Pomoni M, Moschouris H et al. Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc. Intervent. Radiol. 35(5), 1119–1128 (2012).
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM, Han G et al. Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomised, double-blind SPACE trial. J. Clin. Oncol. 30(Suppl. 4), Abstract LBA154 (2012).
   Web of Science ®Google Scholar
• Kudo M, Imanaka K, Chida N et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur. J. Cancer 47(14), 2117–2127 (2011).
   PubMed Web of Science ®Google Scholar
• Hilgard P, Hamami M, Fouly AE et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 52(5), 1741–1749 (2010).
   PubMed Web of Science ®Google Scholar
• Lewandowski RJ, Kulik LM, Riaz A et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am. J. Transplant. 9(8), 1920–1928 (2009).
   PubMed Web of Science ®Google Scholar
• Sangro B, Bilbao JI, Boan J et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 66(3), 792–800 (2006).
   PubMed Web of Science ®Google Scholar
• Sangro B, Carpanese L, Cianni R et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 54(3), 868–878 (2011).
   PubMed Web of Science ®Google Scholar
• Ray CE Jr, Battaglia C, Libby AM, Prochazka A, Xu S, Funaki B. Interventional radiologic treatment of hepatocellular carcinoma-a cost analysis from the payer perspective. J. Vasc. Interv. Radiol. 23(3), 306–314 (2012).
   PubMed Web of Science ®Google Scholar
• Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology 54(1), 173–184 (2011).
   PubMed Web of Science ®Google Scholar
• Hong K, Geschwind JF. Locoregional intra-arterial therapies for unresectable intrahepatic cholangiocarcinoma. Semin. Oncol. 37(2), 110–117 (2010).
   PubMed Web of Science ®Google Scholar
• Scheuermann U, Kaths JM, Heise M et al. Comparison of resection and transarterial chemoembolisation in the treatment of advanced intrahepatic cholangiocarcinoma - A single-center experience. Eur. J. Surg. Oncol. 39(6), 593–600 (2013).
   PubMed Web of Science ®Google Scholar
• Dodson RM, Weiss MJ, Cosgrove D et al. Intrahepatic Cholangiocarcinoma: management options and emerging therapies. J. Am. Coll. Surg. doi:10.1016/j.jamcollsurg.2013.05.021 (2013) (Epub ahead of print).
   Web of Science ®Google Scholar
• Burger I, Hong K, Schulick R et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J. Vasc. Interv. Radiol. 16(3), 353–361 (2005).
   PubMed Web of Science ®Google Scholar
• Vogl TJ, Naguib NN, Nour-Eldin NE et al. Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: Results and prognostic factors governing treatment success. Int. J. Cancer 131(3), 733–740 (2012).
   PubMed Web of Science ®Google Scholar
• Shen WF, Zhong W, Liu Q, Sui CJ, Huang YQ, Yang JM. Adjuvant transcatheter arterial chemoembolization for intrahepatic cholangiocarcinoma after curative surgery: retrospective control study. World J. Surg. 35(9), 2083–2091 (2011).
   PubMed Web of Science ®Google Scholar
• Kuhlmann JB, Euringer W, Spangenberg HC et al. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. Eur. J. Gastroenterol. Hepatol. 24(4), 437–443 (2012).
   PubMed Web of Science ®Google Scholar
• Ibrahim SM, Mulcahy MF, Lewandowski RJ et al. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer 113(8), 2119–2128 (2008).
   PubMed Web of Science ®Google Scholar
• Mouli S, Memon K, Baker T et al. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J. Vasc. Interv. Radiol. 24(8), 1227–1234 (2013).
   PubMed Web of Science ®Google Scholar
• Rafi S, Piduru SM, El-Rayes B et al. Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study. Cardiovasc. Intervent. Radiol. 36(2), 440–448 (2013).
   PubMed Web of Science ®Google Scholar
• Vali M, Liapi E, Kowalski J et al. Intraarterial therapy with a new potent inhibitor of tumor metabolism (3-bromopyruvate): identification of therapeutic dose and method of injection in an animal model of liver cancer. J. Vasc. Interv. Radiol. 18(1 Pt 1), 95–101 (2007).
   PubMed Web of Science ®Google Scholar
• Hernandez-Gea V, Alsinet C, Llovet JM. Oncolytic immunotherapeutic virus in HCC: can it compete with molecular therapies? J. Hepatol. 59(4), 882–884 (2013).
   PubMed Web of Science ®Google Scholar
• Sharma KV, Dreher MR, Tang Y et al. Development of “imageable” beads for transcatheter embolotherapy. J. Vasc. Interv. Radiol. 21(6), 865–876 (2010).
   PubMed Web of Science ®Google Scholar
• Loffroy R, Lin M, Yenokyan G et al. Intraprocedural C-arm dual-phase cone-beam CT: can it be used to predict short-term response to TACE with drug-eluting beads in patients with hepatocellular carcinoma? Radiology 266(2), 636–648 (2013).
   PubMed Web of Science ®Google Scholar
• Lin M, Pellerin O, Bhagat N et al. Quantitative and volumetric European Association for the Study of the Liver and Response Evaluation Criteria in Solid Tumors measurements: feasibility of a semiautomated software method to assess tumor response after transcatheter arterial chemoembolization. J. Vasc. Interv. Radiol. 23(12), 1629–1637 (2012).
   PubMed Web of Science ®Google Scholar
• Bonekamp S, Li Z, Geschwind JF et al. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part I. identification and validation of volumetric functional response criteria. Radiology 268(2), 420–430 (2013).
   PubMed Web of Science ®Google Scholar